[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR066531A1 - Dihidroquinonas y dihidronaftiridinas como inhibidores de las jnk, composicion farmaceutica - Google Patents

Dihidroquinonas y dihidronaftiridinas como inhibidores de las jnk, composicion farmaceutica

Info

Publication number
AR066531A1
AR066531A1 ARP080101996A ARP080101996A AR066531A1 AR 066531 A1 AR066531 A1 AR 066531A1 AR P080101996 A ARP080101996 A AR P080101996A AR P080101996 A ARP080101996 A AR P080101996A AR 066531 A1 AR066531 A1 AR 066531A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
halogen
nr9r10
cycloalkyl
dihydronaftiridins
Prior art date
Application number
ARP080101996A
Other languages
English (en)
Inventor
Leyi Gong
Sarah C Abbot
Genevieve N Boice
Yun-Chou Tan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR066531A1 publication Critical patent/AR066531A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

Los compuestos de la formula (1) son moduladores eficaces de las JNK; en la que X es CR11 o N; X2 es CH o N; R1 y R2 con independencia entre sí son H, halogeno, CN, alquilo inferior o -Y1-Y2-Y3-Y8, o R1 y R2 juntos forman -O(CH2)nO-, en el que n es1 o 2; Y1 es -O-, -C(O)-, -C(O)O-, -C(O)NR9-, -NR9C(O)-, -S- o -SO2-; Y2 es alquileno inferior o un enlace; Y3 es -O-, -C(O)-, -C(O)O-, -C(O)NR9-, -NR9C(O)-, -SO2-o un enlace; R8 es H, alquilo inferior, cicloalquilo, heterocicloalquilo o -NR9R10-,en la que cuando R8 es distinto de H, entonces está opcionalmente sustituido por alquilo inferior, halogeno o -OH; R9 y R10 con independencia entre sí son H o alquilo inferior; R3 es OH, -alquilo inferior, alcoxi inferior o -NR9R10; R4 es alquiloinferior, fenilo, heterociclilo, cicloalquilo, heterocicloalquilo, o heteroarilo, y está opcionalmente sustituido por alquilo inferior, hidroxi, alcoxi inferior, halogeno, nitro, amino, ciano, o halo-alquilo inferior; R5 y R6 con independencia entresí son H, halogeno, ciano, alquilo inferior, -CF3, alcoxi inferior, -OCHF2-, -NO2 o -NR9R10-; R11 es H, alquilo inferior, cicloalquilo inferior o fenilo; o una sal farmacéuticamente aceptable del mismo.
ARP080101996A 2007-05-14 2008-05-12 Dihidroquinonas y dihidronaftiridinas como inhibidores de las jnk, composicion farmaceutica AR066531A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93005407P 2007-05-14 2007-05-14

Publications (1)

Publication Number Publication Date
AR066531A1 true AR066531A1 (es) 2009-08-26

Family

ID=39677349

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101996A AR066531A1 (es) 2007-05-14 2008-05-12 Dihidroquinonas y dihidronaftiridinas como inhibidores de las jnk, composicion farmaceutica

Country Status (17)

Country Link
US (1) US8163906B2 (es)
EP (1) EP2148862B1 (es)
JP (1) JP5160638B2 (es)
KR (1) KR101176711B1 (es)
CN (1) CN101679270B (es)
AR (1) AR066531A1 (es)
AT (1) ATE551326T1 (es)
AU (1) AU2008250049A1 (es)
BR (1) BRPI0811601A2 (es)
CA (1) CA2686385C (es)
CL (1) CL2008001393A1 (es)
ES (1) ES2382137T3 (es)
IL (1) IL201686A0 (es)
MX (1) MX2009012222A (es)
RU (1) RU2466993C2 (es)
TW (1) TW200908974A (es)
WO (2) WO2009015917A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828924B2 (en) * 2009-05-14 2014-09-09 University Of Maryland, Baltimore Methods of treating a diabetic embryopathy
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
CN101985424B (zh) * 2010-09-21 2013-05-29 浙江工业大学 一种合成邻硝基苯乙酮类化合物的方法
US8471027B2 (en) * 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
JP6018633B2 (ja) * 2011-07-12 2016-11-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アミノメチルキノロン化合物
ES2704232T3 (es) * 2013-08-29 2019-03-15 Kyoto Pharma Ind Compuesto aromático y uso del mismo en el tratamiento de trastornos asociados con el metabolismo óseo
CN105936635B (zh) * 2015-03-06 2019-06-21 南京圣和药业股份有限公司 作为磷脂酰肌醇3-激酶δ抑制剂的化合物及其应用
CN106008479B (zh) 2015-03-06 2020-01-10 南京圣和药业股份有限公司 作为磷脂酰肌醇3-激酶δ抑制剂的取代嘧啶类化合物及其应用
KR102431342B1 (ko) 2015-10-02 2022-08-10 에프. 호프만-라 로슈 아게 Pd1 및 tim3에 특이적인 이중특이성 항체
CN107602465A (zh) * 2016-07-12 2018-01-19 重庆大学 一种喹诺酮类衍生物及其应用
MY201482A (en) 2017-04-03 2024-02-26 Hoffmann La Roche Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
JP6997212B2 (ja) 2017-04-05 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ１及びｌａｇ３に特異的に結合する二重特異性抗体
US20230142739A1 (en) * 2020-04-03 2023-05-11 The Regents Of The University Of California Protein-protein interaction stabilizers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2733233B1 (fr) * 1995-04-20 1997-05-30 Roussel Uclaf Nouveaux derives de quinoleine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
US6080757A (en) 1996-06-06 2000-06-27 Pfizer Inc Antibiotic quinolones and derivatives
JP2002514192A (ja) 1996-11-13 2002-05-14 セフアロン・インコーポレーテツド ベンゾチアゾおよび関連の複素環基を含有するシステインおよびセリンプロテアーゼ阻害剤
AR035016A1 (es) * 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
WO2002076939A2 (en) * 2001-02-05 2002-10-03 Exegenics Inc. Cysteine protease inhibitors
US7973064B2 (en) * 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
SE0104331D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Novel compounds
AU2003211931A1 (en) * 2002-02-13 2003-09-04 Takeda Chemical Industries, Ltd. Jnk inhibitor
WO2004014388A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
RU2275361C3 (ru) * 2002-11-20 2021-10-01 Джапан Тобакко Инк. Соединение 4-оксохинолина и его применение в качестве ингибитора вич интегразы
WO2005014576A1 (ja) 2003-08-12 2005-02-17 Takeda Pharmaceutical Company Limited イソキノリノン誘導体、その製造法および用途
WO2005091857A2 (en) * 2004-03-12 2005-10-06 Bayer Pharmaceuticals Corporation 1,6-naphthyridine and 1,8-naphthyridine derivatives and their use to treat diabetes and related disorders
JO2959B1 (en) 2007-05-14 2016-03-15 جانسين فارماسوتيكا ان. في Mono-hydrochloric salts for histone dacetylase inhibitor

Also Published As

Publication number Publication date
EP2148862A1 (en) 2010-02-03
JP2010527341A (ja) 2010-08-12
WO2008138920A1 (en) 2008-11-20
JP5160638B2 (ja) 2013-03-13
IL201686A0 (en) 2010-05-31
RU2466993C2 (ru) 2012-11-20
WO2009015917A2 (en) 2009-02-05
CA2686385C (en) 2016-01-12
KR20100007987A (ko) 2010-01-22
KR101176711B1 (ko) 2012-08-23
CN101679270A (zh) 2010-03-24
TW200908974A (en) 2009-03-01
CN101679270B (zh) 2013-05-01
ATE551326T1 (de) 2012-04-15
AU2008250049A1 (en) 2008-11-20
EP2148862B1 (en) 2012-03-28
US20080287458A1 (en) 2008-11-20
MX2009012222A (es) 2009-12-01
ES2382137T3 (es) 2012-06-05
US8163906B2 (en) 2012-04-24
RU2009146124A (ru) 2011-06-20
BRPI0811601A2 (pt) 2019-08-27
CL2008001393A1 (es) 2009-05-22
CA2686385A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
AR066531A1 (es) Dihidroquinonas y dihidronaftiridinas como inhibidores de las jnk, composicion farmaceutica
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR106945A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
AR057380A1 (es) Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR079226A1 (es) Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
PE20121282A1 (es) Antagonistas de espiro-oxindol de mdm2
RS51007B (sr) Supstituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz toga
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
AR076067A1 (es) Composiciones y metodos para modular la senda de senalizacion de wnt
PE20141791A1 (es) Compuestos de enediino, conjugados de los mismos y sus usos y metodos
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR045687A1 (es) Macrociclos derivados de la quinazolina, procesos de preparacion y composiciones farmaceuticas que los contienen
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR071763A1 (es) Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos

Legal Events

Date Code Title Description
FB Suspension of granting procedure